A Small Molecule AMPK Activator Protects the Heart Against Ischemia-reperfusion Injury

Overview

Journal J Mol Cell Cardiol

Specialty Cardiology & Vascular Diseases

Date 2011 Mar 16

PMID 21402077

Citations 68

Authors

Agnes S Kim

Edward J Miller

Tracy M Wright

Ji Li

Dake Qi

Kwame Atsina

Vlad Zaha

Kei Sakamoto

Lawrence H Young

Affiliations

Soon will be listed here.

Abstract

AMP-activated protein kinase (AMPK) is a stress signaling enzyme that orchestrates the regulation of energy-generating and -consuming pathways. Intrinsic AMPK activation protects the heart against ischemic injury and apoptosis, but whether pharmacologic AMPK stimulation mitigates ischemia-reperfusion damage is unknown. The aims of this study were to determine whether direct stimulation of AMPK using a small molecule activator, A-769662, attenuates myocardial ischemia-reperfusion injury and to examine its cardioprotective mechanisms. Isolated mouse hearts pre-treated with A-769662 had better recovery of left ventricular contractile function (55% vs. 29% of baseline rate-pressure product; p=0.03) and less myocardial necrosis (56% reduction in infarct size; p<0.01) during post-ischemic reperfusion compared to control hearts. Pre-treatment with A-769662 in vivo attenuated infarct size in C57Bl/6 mice undergoing left coronary artery occlusion and reperfusion compared to vehicle (36% vs. 18%, p=0.025). Mouse hearts with genetically inactivated AMPK were not protected by A-769662, indicating the specificity of this compound. Pre-treatment with A-769662 increased the phosphorylation and inactivation of eukaryotic elongation factor 2 (eEF2), preserved energy charge during ischemia, delayed the development of ischemic contracture, and reduced myocardial apoptosis and necrosis. A-769662 also augmented endothelial nitric oxide synthase (eNOS) activation during ischemia, which partially attenuated myocardial stunning, but did not prevent necrosis. AMPK is a therapeutic target that can be stimulated by a direct-acting small molecule in order to prevent injury during ischemia-reperfusion. The use of AMPK activators may represent a novel strategy to protect the heart and other solid organs against ischemia.

Citing Articles

Molecular Mechanisms Underlying Heart Failure and Their Therapeutic Potential.

Fonseka O, Gare S, Chen X, Zhang J, Alatawi N, Ross C Cells. 2025; 14(5).

PMID: 40072053 PMC: 11899429. DOI: 10.3390/cells14050324.

Subacute Reperfusion in Ischemic Hearts: Study of Autophagy and its Possible Interconnection with Receptor-Interacting Protein Kinase 3.

Horvath C, Ravingerova T, Suleiman M, Adameova A Rev Cardiovasc Med. 2024; 23(6):213.

PMID: 39077170 PMC: 11273659. DOI: 10.31083/j.rcm2306213.

Mitochondrial Kinase Signaling for Cardioprotection.

Boengler K, Eickelmann C, Kleinbongard P Int J Mol Sci. 2024; 25(8).

PMID: 38674076 PMC: 11049936. DOI: 10.3390/ijms25084491.

Bioinformatics integration reveals key genes associated with mitophagy in myocardial ischemia-reperfusion injury.

Chen Z, Liu T, Yuan H, Sun H, Liu S, Zhang S BMC Cardiovasc Disord. 2024; 24(1):183.

PMID: 38539069 PMC: 10967080. DOI: 10.1186/s12872-024-03834-x.

Dapagliflozin Alleviates Myocardial Ischaemia Reperfusion Injury by Activating Mitophagy the AMPK-PINK1/Parkin Signalling Pathway.

Zuo W, Wang L, Tian R, Wang L, Liu Y, Qian H Curr Vasc Pharmacol. 2023; 22(3):203-217.

PMID: 38141195 DOI: 10.2174/0115701611269801231211104905.

References

Tsuchida A, Yang X, Burckhartt B, Mullane K, Cohen M, Downey J . Acadesine extends the window of protection afforded by ischaemic preconditioning. Cardiovasc Res. 1994; 28(3):379-83. DOI: 10.1093/cvr/28.3.379. View

Shinmura K, Tamaki K, Bolli R . Short-term caloric restriction improves ischemic tolerance independent of opening of ATP-sensitive K+ channels in both young and aged hearts. J Mol Cell Cardiol. 2005; 39(2):285-96. DOI: 10.1016/j.yjmcc.2005.03.010. View

Chan A, Soltys C, Young M, Proud C, Dyck J . Activation of AMP-activated protein kinase inhibits protein synthesis associated with hypertrophy in the cardiac myocyte. J Biol Chem. 2004; 279(31):32771-9. DOI: 10.1074/jbc.M403528200. View

Qi D, Hu X, Wu X, Merk M, Leng L, Bucala R . Cardiac macrophage migration inhibitory factor inhibits JNK pathway activation and injury during ischemia/reperfusion. J Clin Invest. 2009; 119(12):3807-16. PMC: 2786800. DOI: 10.1172/JCI39738. View

Wang Y, Gao E, Tao L, Lau W, Yuan Y, Goldstein B . AMP-activated protein kinase deficiency enhances myocardial ischemia/reperfusion injury but has minimal effect on the antioxidant/antinitrative protection of adiponectin. Circulation. 2009; 119(6):835-44. PMC: 2658653. DOI: 10.1161/CIRCULATIONAHA.108.815043. View

Li J, Hu X, Selvakumar P, Russell 3rd R, Cushman S, Holman G . Role of the nitric oxide pathway in AMPK-mediated glucose uptake and GLUT4 translocation in heart muscle. Am J Physiol Endocrinol Metab. 2004; 287(5):E834-41. DOI: 10.1152/ajpendo.00234.2004. View

Nishino Y, Miura T, Miki T, Sakamoto J, Nakamura Y, Ikeda Y . Ischemic preconditioning activates AMPK in a PKC-dependent manner and induces GLUT4 up-regulation in the late phase of cardioprotection. Cardiovasc Res. 2004; 61(3):610-9. DOI: 10.1016/j.cardiores.2003.10.022. View

Benziane B, Bjornholm M, Lantier L, Viollet B, Zierath J, Chibalin A . AMP-activated protein kinase activator A-769662 is an inhibitor of the Na(+)-K(+)-ATPase. Am J Physiol Cell Physiol. 2009; 297(6):C1554-66. DOI: 10.1152/ajpcell.00010.2009. View

Kalender A, Selvaraj A, Kim S, Gulati P, Brule S, Viollet B . Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab. 2010; 11(5):390-401. PMC: 3081779. DOI: 10.1016/j.cmet.2010.03.014. View

10.

Marsin A, Bertrand L, Rider M, Deprez J, Beauloye C, Vincent M . Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia. Curr Biol. 2000; 10(20):1247-55. DOI: 10.1016/s0960-9822(00)00742-9. View

11.

Cool B, Zinker B, Chiou W, Kifle L, Cao N, Perham M . Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab. 2006; 3(6):403-16. DOI: 10.1016/j.cmet.2006.05.005. View

12.

Gruber H, Hoffer M, McAllister D, Laikind P, Lane T, Engler R . Increased adenosine concentration in blood from ischemic myocardium by AICA riboside. Effects on flow, granulocytes, and injury. Circulation. 1989; 80(5):1400-11. DOI: 10.1161/01.cir.80.5.1400. View

13.

Wang G, Liem D, Vondriska T, Honda H, Korge P, Pantaleon D . Nitric oxide donors protect murine myocardium against infarction via modulation of mitochondrial permeability transition. Am J Physiol Heart Circ Physiol. 2004; 288(3):H1290-5. DOI: 10.1152/ajpheart.00796.2004. View

14.

Sumeray M, Rees D, Yellon D . Infarct size and nitric oxide synthase in murine myocardium. J Mol Cell Cardiol. 2000; 32(1):35-42. DOI: 10.1006/jmcc.1999.1050. View

15.

Shibata R, Sato K, Pimentel D, Takemura Y, Kihara S, Ohashi K . Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med. 2005; 11(10):1096-103. PMC: 2828682. DOI: 10.1038/nm1295. View

16.

Foretz M, Hebrard S, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G . Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest. 2010; 120(7):2355-69. PMC: 2898585. DOI: 10.1172/JCI40671. View

17.

Murry C, Jennings R, Reimer K . Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986; 74(5):1124-36. DOI: 10.1161/01.cir.74.5.1124. View

18.

Kudo N, Barr A, Barr R, Desai S, Lopaschuk G . High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5'-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase. J Biol Chem. 1995; 270(29):17513-20. DOI: 10.1074/jbc.270.29.17513. View

19.

Chen Z, Mitchelhill K, Michell B, Stapleton D, Rodriguez-Crespo I, Witters L . AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Lett. 1999; 443(3):285-9. DOI: 10.1016/s0014-5793(98)01705-0. View

20.

Horman S, Browne G, Krause U, Patel J, Vertommen D, Bertrand L . Activation of AMP-activated protein kinase leads to the phosphorylation of elongation factor 2 and an inhibition of protein synthesis. Curr Biol. 2002; 12(16):1419-23. DOI: 10.1016/s0960-9822(02)01077-1. View